In the current study, wedemonstrated enhanced immune cell recruitment and reduced T cell co-inhibitory pathwaysin tumors that lack mammary epithelial expression of the pro-inflammatory enzyme COX-2,coincident with delayed ErbB2 oncogene-driven mammary tumor development. Here, ERBB2 is linked to breast cancer.